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Abstract
Background: Aldosterone levels are elevated in a rat model of type 2 diabetes mellitus, the Zucker Diabetic fatty
rat (ZDF). Moreover blood pressure in ZDF rats is salt-sensitive. The aim of this study was to examine the effect of
the aldosterone antagonist eplerenone on structural and mechanical properties of resistance arteries of ZDF-rats on
normal and high-salt diet.
Methods: After the development of diabetes, ZDF animals were fed either a normal salt diet (0.28%) or a high-salt
diet (5.5%) starting at an age of 15 weeks. ZDF rats on high-salt diet were randomly assigned to eplerenone (100
mg/kg per day, in food) (ZDF+S+E), hydralazine (25 mg/kg per day) (ZDF+S+H), or no treatment (ZDF+S). Rats on
normal salt-diet were assigned to eplerenone (ZDF+E) or no treatment (ZDF). Normoglycemic Zucker lean rats
were also divided into two groups receiving normal (ZL) or high-salt diet (ZL+S) serving as controls. Systolic blood
pressure was measured by tail cuff method. The experiment was terminated at an age of 25 weeks. Mesenteric
resistance arteries were studied on a pressurized myograph. Specifically, vascular hypertrophy (media-to-lumen
ratio) and vascular stiffness (strain and stress) were analyzed. After pressurized fixation histological analysis of
collagen and elastin content was performed.
Results: Blood pressure was significantly higher in salt-loaded ZDF compared to ZDF. Eplerenone and hydralazine
prevented this rise similarily, however, significance niveau was missed. Media-to-lumen ratio of mesenteric
resistance arteries was significantly increased in ZDF+S when compared to ZDF and ZL. Both, eplerenone and
hydralazine prevented salt-induced vascular hypertrophy. The strain curve of arteries of salt-loaded ZDF rats was
significantly lower when compared to ZL and when compared to ZDF+S+E, but was not different compared to
ZDF+S+H. Eplerenone, but not hydralazine shifted the strain-stress curve to the right indicating a vascular wall
composition with less resistant components. This indicates increased vascular stiffness in salt-loaded ZDF rats,
which could be prevented by eplerenone but not by hydralazine. Collagen content was increased in ZL and ZDF
rats on high-salt diet. Eplerenone and hydralazine prevented the increase of collagen content. There was no
difference in elastin content.
Conclusion: Eplerenone and hydralazine prevented increased media-to-lumen ratio in salt-loaded ZDF-rats,
indicating a regression of vascular hypertrophy, which is likely mediated by the blood pressure lowering-effect.
Eplerenone has additionally the potential to prevent increased vascular stiffness in salt-loaded ZDF-rats. This
suggests an effect of the specific aldosterone antagonist on adverse vascular wall remodelling.
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Background
The renin-angiotensin-aldosterone system (RAAS) plays
a key role in the pathophysiology of hypertension and
vascular complications of diabetes mellitus. The minera-
locorticoid aldosterone is a well established target in the
pharmacotherapy of congestive heart failure and hyper-
tension [1,2]. Specific inhibition of the mineralocorticoid
receptor on top of ACE inhibitor medication has
recently been implicated as a new therapeutic strategy
to improve the coronary circulation in diabetics. Aldos-
terone antagonism has also demonstrated potential to
protect from certain cardiovascular and other end-organ
damage in animal models. Spironolactone or the more
specific antagonist eplerenone prevented left ventricular
inflammation and fibrosis [3-6], renal inflammation and
proteinuria [7,8], stiffening of the carotid artery [9-12],
resistance artery remodelling, endothelial dysfunction,
and activation of NADPH oxidase [13,14]. Eplerenone
has been shown to reduce resistance artery stiffness in
hypertensive patients [15]. In diabetes mellitus aldoster-
one antagonism effectively reduces renal injury irrespec-
tive of the species or specific cause of diabetes [16]. We
previously reported a state of hyporeninemic hyperal-
dosteronism in a model of type II diabetes mellitus, the
Zucker Diabetic Fatty ZDF-rat [17]. However, it is
unclear if specific aldosterone antagonism is also able to
prevent remodelling and stiffening of resistance arteries
in this model of diabetes mellitus.
Most studies using mineralocorticoid receptor antag-
onism in aldosterone-infused rats [3-5,7,9] or in stroke
prone spontaneously hypertensive rats were performed
after salt loading [18,19]. It has been suggested that
aldosterone suppression may be impaired in salt loaded
ZDF both with regard to plasma aldosterone concentra-
tions [20] and tissue specific aldosterone synthase activ-
ity [21,22]. The detailed role of aldosterone in the salt
induced aggravation of end organ damage in ZDF rats is
unclear.
Aim of the present study was to test the impact of the
specific mineralocorticoid antagonist eplerenone on salt-
induced vascular remodeling and vascular stiffness in
ZDF rats receiving normal and high dietary salt intake.
Methods
Animal experiments
The study was approved by the local committee on ani-
mal research and adhered for the “Guide for the Care
and Use of Laboratory Animals” published by the US
National Institutes of Health. Male ZDF (fa/fa) (Charles
River Laboratories, Wilmington, MA) rats with a geneti-
cally induced form of type 2 diabetes including severe
hyperglycemia and their normoglycemic controls, the
Zucker lean (ZL) (Charles River Laboratories, Wilming-
ton, MA) rats were studied. Rats were fed Purina 5008
rat chow (Charles River Laboratories) containing 29.2%
protein, 7% fat, 52.3% carbohydrates, 4.3% fiber and
7.2% ash. They received tap water ad libitum. Rats were
individually housed on a 12-h dark/12-h light cycle.
After development of diabetes animals were divided into
7 groups. ZL and ZDF rats received either normal-salt
(0.28% NaCl) (ZL, n = 9) (ZDF, n = 9) or high-salt diet
(5.5% NaCl in chow) (ZL+S, n = 9) (ZDF+S, n = 8) for
10 weeks starting at an age of 15 weeks. Two additional
groups of normal-salt and high-salt treated ZDF rats
received eplerenone (100 mg/kg body weight per day in
chow; Pharmacia/Pfizer) (ZDF + E, n = 8) (ZDF+S+E, n
= 8). To control for effects of blood pressure lowering
one group of ZDF rats on high salt diet received orally
the vasodilator hydralazine (25 mg/kg body weight per
day) (ZDF+S+H, n = 7). Serum glucose was measured
weekly from an incision in the tail vein (Accu-Check
Sensor, Roche, Mannheim, Germany). Systolic blood
pressure (SBP) was measured weekly by the tail cuff
method using an automated cuff inflator-pulse system
(W+W electronic AG, BPrecorder No. 8005, Basel, Swit-
zerland). The experiment was terminated at week 25 by
decapitation of the rats. Blood was collected and plasma
samples immediately frozen for further analysis. The
mesenteric vasculature was dissected, and one segment
was used for preparation of small arteries.
Preparation and Study of Small Arteries
A 3rd order branch of the superior mesenteric artery
was carefully dissected and mounted on a pressurized
myograph (111 P; Danish Myo Technology, Aarhus,
Denmark). Perfusion was performed using oxygenated
37°C Krebs solution (95% O2, 5% CO2) pH 7.4 contain-
ing (mmol-1): NaCl (118), KH2PO4 (1.18), KCl (4.7),
MgSO4 (1.18), CaCl2 (2.5), D-Glucose (5.5), NAHCO3
(25) and EDTA (0.026) as described previously [23].
Vessels were equilibrated under a constant pressure of
45 mmHg. Vascular reactivity was tested with a single
dose of norepinephrine (10-5 mol/L-1). After precontrac-
tion with 10-5 mol/L norepinephrine, endothelium
dependent relaxation was assessed with acetylcholine
(10-4 mol/L). Vascular morphology and mechanics was
assessed under resting conditions at three different
points along the vessel. For assessment of passive
mechanical properties, arteries were deactivated of myo-
genic tone by calcium-depletion (Ca2+-free KREBS solu-
tion containing EDTA 10 mmol/l for 30 min). Then
intravascular pressure was increased from 3 to 10, 20,
30, and 40 mmHg and afterward in 20-mmHg steps up
to 140 mmHg. The pressure was maintained at each
pressure step until stable conditions were reached to
allow the vessel to reach a steady-state diameter. The
changes in internal diameter as well as media thickness
of vessels in response to each increase in intravascular
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pressure were measured at three points along the vessel
with the use of a calibrated video system (111 P, Danish
Myo Technology, Aarhus, Denmark). At last vessels
were fixed for histological analysis.
Histology
Third order mesenteric arteries were pressurized at 45
mmHg, fixed with 2% paraformaldehyde solution at
room temperature for 30 minutes, removed from the
cannula, and processed for histological analysis. Paraffin
embedded tissue sections of mesenteric arteries were
stained with Sirius red F3BA (0,5% in saturated aqueous
picric acid, Sigma Aldrich chemical Company, Stein-
heim, Germany). Collagen content in the media was
quantified light microscopically with the Northern
Eclipse imaging program (EM-PIX Imaging Inc.) and
was determined by measuring the relative density per
area in each Sirius red-stained section.
Immunhistochemistry
Paraffin sections were dewaxed in sequential xylol and
isopropyl alcohol to distilled water. Endogenous peroxi-
dase activity was quenched by incubation with 3% H2O2
for 20 min at room temperature. For collagen IV exami-
nation sections were incubated with the primary anti-
body (goat anti-rat polyclonal antibody, 1:100, 37°C for
60 min; Southern biotech) after blocking with normal
rabbit serum (30 min, room temperature). After rinsing
in PBS, sections were incubated with the second anti-
body (biotinylated anti-goat, 1:100, 30 min, room tem-
perature; Vector Laboratories, Inc., Burlingame, CA,
USA). Antibody-antigen complexes were detected using
a Vectastain Elite ABC kit (Vector). Then the label com-
plex was applied (AEC Kit; Vector) for 7.5 min. Colour
development was stopped under microscopic control by
adding water, and sections were finally counterstained
using haemoxylin. For examination of elastin content
immunohistochemistry was performed in a similar man-
ner. After blocking with normal goat serum (30 min,
room temperature) rabbit anti-rat polyclonal antibody
served as primary antibody (1:100 dilution, 37°C for 60
min; Chemicon International, Inc., Temecula, CA, USA).
After rinsing in PBS, we used biotinylated anti-rabbit
(1:100, 30 min, room temperature; Vector Laboratories,
Inc., Burlingame, CA, USA) as second antibody and per-
formed the further investigation steps identical to the
collagen IV examination.
Plasma Aldosterone Levels
Blood samples were centrifugated at 4°C, and the plasma
was saved for subsequent analysis. Plasma aldosterone
levels were measured by radioimmunoassay with the use
of commercially available kit (DiaSorin, Dietzenbach,
Germany), according to the manufacturer’s instructions.
Data Analysis
Data are presented as mean ± SEM. For systolic blood
pressure levels, mean values of weekly measurements
throughout active treatment were calculated for each
animal. Circumferential stress which corresponds to
wall tension or the distending force on the vessel wall
was calculated as s = (PDi)/(2 M), where P was intra-
luminal pressure, and Di and M were lumen diameter
and media thickness, respectively. Circumferential strain
which corresponds to pressure-induced relative
increases in lumen diameter was calculated as ε = (D -
D0)/D0 where D was the observed lumen diameter at a
given intraluminal pressure and D0 was the original dia-
meter measured at 3 mmHg, respectively. The strain-
stress relation was fitted to an exponential curve for
each vessel and the slope for each curve was deter-
mined. Groups were compared using 1-way ANOVA, or
2-way ANOVA for repeated measurements as appropri-
ate. Post-hoc testing was performed using LSD test (1-
way ANOVA and 2-way ANOVA for repeated mea-
sures). A p-value of < 0.05 was considered significant.
Statistical analyses were performed using SigmaStat 3.0
software and SPSS 18 software (SPSS GmbH,
Muenchen, Germany).
Results
Animal data
The non-diabetic ZL rats tended to start with a statisti-
cally insignificant lower body weight compared to the
ZDF rats. At the end of the study there were no relevant
differences in body weights (Table 1). ZL rats were nor-
moglycemic irrespective of their salt intake. ZDF rats
displayed significantly elevated serum glucose levels
throughout the study. Interestingly, serum glucose levels
were significantly lower in ZDF + S rats as compared
with ZDF rats on the normal diet (Table 1).
As previously reported [24], SBP was lower in ZDF
rats compared to ZL rats at the start of the treatment.
After 10 weeks of salt loading blood pressure was signif-
icantly higher in ZDF rats on high salt diet as compared
to normal salt diet, while there was no significant differ-
ence between ZL rats on high and normal salt diet
(Table 1). Both, eplerenone and hydralazine treatment
did result in a not significant blood pressure reduction
in salt loaded ZDF animals (- 5 mmHg ZDF+S+E, - 4
mmHg ZDF+S+H; p = ns) (Table 1). SBP was not differ-
ent in the ZDF+E and ZDF+S+E groups. Thus, eplere-
none prevented at least partially the salt induced rise in
blood pressure.
Confirming previous findings [17] plasma aldosterone
levels were higher in ZDF than in ZL rats. High salt
diet completely suppressed circulating aldosterone activ-
ity in normoglycemic ZL but not in diabetic ZDF rats
(Figure 1).
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Morphology and Mechanical Properties of Mesenteric
Arteries
Media thickness of mesenteric resistance arteries signifi-
cantly increased with salt-loading in ZDF rats as previously
reported [24]. Eplerenone and hydralazine prevented the
increase of media thickness in animals on high-salt diet
(Table 2). Media-to-lumen ratio was increased with higher
salt intake (Table 2). This was prevented by eplerenone.
Treatment with eplerenone was only effective in animals
on high-salt diet. Hydralazine prevented the increase of
media-to-lumen ratio to a similar extent like eplerenone
in salt treated ZDF rats (Table 2).
The strain curve of arteries of salt-loaded ZDF rats
was significantly lower when compared with ZL rats (p
Table 1 Biometric, serum and metabolic data:
ZL ZL+S ZDF ZDF+E ZDF+S ZDF+S
+E
ZDF+S
+H
P-
value
n 9 9 9 8 8 8 7
Body weight at week 14 (g) 325 ±
5
335 ±
7
341 ±
13
345 ± 9 357 ± 10 347 ± 8 360 ± 9 0.11
Body weight at week 24 (g) 381 ±
7
372 ±
8
362 ±
13
365 ±
13
371 ± 18 348 ± 10 369 ± 13 0.60
Serum glucose levels (mg per 100 ml) at week 14 95 ± 7* 96 ± 9* 377 ±
22
363 ±
15
344 ± 19 375 ± 7 389 ± 24 < 0.001
Serum glucose levels (mg per 100 ml) at week 24 91 ± 7* 83 ± 5* 408 ±
21
425 ±
27
319 ±
30♠
367 ± 34 364 ± 20 < 0.001
Mean systolic blood pressure over treatment periode
(mmHg)
147 ±
3
150 ±
3
134 ± 3
¥
138 ± 3 144 ± 4¥¥ 139 ± 4 140 ± 3 < 0.001
Abbreviations: ZL: Zucker lean on normal diet. ZL + S: Zucker lean on high salt diet. ZDF: Zucker diabetic fatty. ZDF + E: Zucker diabetic fatty on eplerenone
therapy. ZDF + S: Zucker diabetic fatty on high salt diet. ZDF + S + E: Zucker diabetic fatty on high salt diet with eplerenone therapy. ZDF + S + H: Zucker
diabetic fatty on high salt diet with hydralazine therapy.
Post hoc testing: * P < 0.001 ZL and ZL + S vs. all other groups. ¥ P < 0.001 ZDF vs. ZL. ¥¥ P < 0.01 ZDF + S vs. ZDF. ♠ P < 0.05 ZDF + S vs. ZDF.
L L+S F F+E F+S F+S+E F+S+H
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Figure 1 Plasma aldosterone concentration (pg/ml). Analysis of variance * p < 0.001 ZDF + E vs. all other groups. L: Zucker lean on normal
diet. L + S: Zucker lean on high salt diet. F: Zucker diabetic fatty. F + E: Zucker diabetic fatty on eplerenone therapy. F + S: Zucker diabetic fatty
on high salt diet. F + S + E: Zucker diabetic fatty on high salt diet with eplerenone therapy. F + S + H: Zucker diabetic fatty on high salt diet
with hydralazine therapy.
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< 0.05) and when compared with salt-loaded ZDF rats
treated with eplerenone (p < 0.05), but was not differ-
ent compared to salt-loaded ZDF rats treated with
hydralazine (p = 0.80) (Figure 2). This indicates
increased vascular stiffness in salt-loaded ZDF rats,
which could be prevented by eplerenone but not by
hydralazine. The stress curve of arteries of salt-loaded
ZDF rats was significantly lower when compared with
ZL rats (p < 0.05), ZDF rats (p < 0.05), salt loaded
ZDF rats treated with eplerenone (p < 0.05), and salt-
loaded ZDF rats treated with hydralazine (p < 0.05),
indicating that increased stiffness in salt loaded ZDF
rats is at least in part geometry dependent (Figure 3).
For further analysis of geometry independent stiffness
the strain-stress curves were plotted. Eplerenone, but
not hydralazine shifted the strain-stress curve to the
right indicating a vascular wall composition with less
resistant components (Figure 4). Accordingly, the
exponent of the fitted exponential curve (Table 2) was
increased in salt-treated ZDF rats. This increase was
prevented by eplerenone but not by hydralazine. How-
ever, the significance niveau was missed (p = 0.09),
which is likely due to the complex mathematical trans-
formations necessary for this analysis.
Table 2 Structural, histological and immunohistochemical characteristics of mesenteric resistance arteries:
ZL ZL+S ZDF ZDF+E ZDF+S ZDF+S+E ZDF+S+H P-value
Media (μm) 17.9 ± 0.9 22.2 ± 1.9 19.8 ± 0.9 21.1 ± 1.1 28.7 ± 1.8◆ 22.6 ± 2.0 23.6 ± 1.2 < 0.001
Lumen (μm) 297 ± 14 306 ± 22 298 ± 11 301 ± 21 273 ± 12 305 ± 13 302 ± 17 0.82
Media/Lumen (%) 6.1 ± 0.3 7.3 ± 0.3 6.7 ± 0.3 7.1 ± 0.3 10.7 ± 0.8♠ 7.5 ± 0.7 7.9 ± 0.4 < 0.001
Exponent
Strain/stress relation
6.4 ± 0.4 6.3 ± 0.3 6.5 ± 0.5 5.7 ± 0.3 7.5 ± 0.6 5.6 ± 0.3 6.4 ± 0.7 0.09
Collagen IV (%) 17.1 ± 0.7 25.9 ± 0.4* 20.9 ± 0.7§ 18.3 ± 0.4¥¥ 27.0 ± 0.4¥ 21.3 ± 0.4¡ 21.5 ± 0.5¡ ¡ < 0.001
Elastin (%) 21.6 ± 1.3 15.6 ± 1.2 18.8 ± 1.2 23.5 ± 1.4 17.6 ± 2.0 18.0 ± 1.2 19.2 ± 0.6 0.01
Sirius red (%) 12.1 ± 0.4 19.0 ± 0.9 16.2 ± 0.6 17.2 ± 0.6 19.6 ± 0.6♤ 17.5 ± 0.9 17.1 ± 0.7✚ < 0.001
Abbreviations: ZL: Zucker lean on normal diet. ZL + S: Zucker lean on high salt diet. ZDF: Zucker diabetic fatty. ZDF + E: Zucker diabetic fatty on eplerenone
therapy. ZDF + S: Zucker diabetic fatty on high salt diet. ZDF + S + E: Zucker diabetic fatty on high salt diet with eplerenone therapy. ZDF + S + H: Zucker
diabetic fatty on high salt diet with hydralazine therapy.
Post hoc testing: * P < 0.001 ZL vs. ZL+S. § P < 0.001 ZL vs. ZDF. ¥ P < 0.001 ZDF vs. ZDF+S. ¥¥ p < 0.001 ZDF vs. ZDF+E. ¡ P < 0.001 ZDF+S vs. ZDF+S+E. ¡ ¡ p <
0.001 ZDF+S vs. ZDF+S+H. ◆ P < 0.05 ZDF+S vs. all other groups. ♠ P < 0.001 ZDF+S vs. all other groups. ♤ P < 0.05 ZDF vs. ZDF + S. ✚ p < 0.05 ZDF + S
vs. ZDF + S + H.
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Figure 2 Mechanical characteristics of mesenteric resistance arteries: Strain plotted against intraluminal pressure. ZL: Zucker lean on
normal diet. ZL + S: Zucker lean on high salt diet. ZDF: Zucker diabetic fatty. ZDF + S: Zucker diabetic fatty on high salt diet. ZDF + S + E:
Zucker diabetic fatty on high salt diet with eplerenone therapy. ZDF + S + H: Zucker diabetic fatty on high salt diet with hydralazine therapy.
Resch et al. Cardiovascular Diabetology 2011, 10:94
http://www.cardiab.com/content/10/1/94
Page 5 of 9
Collagen and Elastin Content of Mesenteric Arteries
Collagen content in the media of mesenteric resistance
arteries was significantly increased with salt loading (p
< 0.001 ZL vs. ZL+S and p < 0.001 ZDF vs. ZDF+S for
collagen IV). Eplerenone but also hydralazine treat-
ment significantly reduced the content of media
collagen IV in salt treated ZDF rats (p < 0.001; Table
2; Figure 5). Sirius red results paralleled the collagen
IV findings indicating higher levels in salt treated
groups that could be prevented both either with epler-
enone (just missing the significance niveau with p =
0.062) or with hydralazine (p < 0.05). There were no
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Figure 4 Mechanical characteristics of mesenteric resistance arteries: Strain - Stress relationship. ZL: Zucker lean on normal diet. ZL + S:
Zucker lean on high salt diet. ZDF: Zucker diabetic fatty. ZDF + S: Zucker diabetic fatty on high salt diet. ZDF + S + E: Zucker diabetic fatty on
high salt diet with eplerenone therapy. ZDF + S + H: Zucker diabetic fatty on high salt diet with hydralazine therapy.
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Figure 3 Mechanical characteristics of mesenteric resistance arteries: Stress plotted against intraluminal pressure. ZL: Zucker lean on
normal diet. ZL + S: Zucker lean on high salt diet. ZDF: Zucker diabetic fatty. ZDF + S: Zucker diabetic fatty on high salt diet. ZDF + S + E:
Zucker diabetic fatty on high salt diet with eplerenone therapy. ZDF + S + H: Zucker diabetic fatty on high salt diet with hydralazine therapy.
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significant differences in elastin content between the
different treatment groups.
Discussion
The major finding of our present study was, that specific
inhibition of the mineralocorticoid aldosterone by epler-
enone can effectively prevent stiffening of mesenteric
resistance arteries in salt-loaded diabetic ZDF rats. The
beneficial effect of eplerenone treatment on vascular
stiffness was not present in the hydralazine treated con-
trol animals, indicating a specific impact of the
aldosterone antagonism and not a non-specific effect of
blood pressure reduction. Interestingly, we could
observe that both agents resulted in ZDF+S animals in a
similar reduction of the media-to-lumen-ratio as the
usual measure to describe general vascular remodelling.
This is likely to be mediated by the equal therapeutic
efficacy on blood pressure reduction of eplerenone and
hydralazine in our model. But eplerenone displayed an
additional beneficial and apparently vessel geometry-
independent effect on the development of vascular
stiffness.
Collagen IV
ZL + saltZL
ZDF+ eplerenone
+ salt
ZDF + hydralazine
+ salt
ZDF + saltZDF
ZDF + eplerenone
Figure 5 Representative images of immunohistochemical staining of Collagen IV in the media of mesenteric resistance arteries.
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Indeed, analysis of the strain-stress curve for geome-
try-independent stiffness demonstrated decreased values
in the eplerenone- but not in the hydralazine-treated
ZDF+S rats. Analysis of the slopes of the strain-stress
curves just missed the significance niveau, which is
likely due to the complex mathematical transformations
necessary for this analysis. Also other studies have
found increased vascular stiffness in ZDF rats [25]. In
that study the treatment with rosiglitazone was able to
improve endothelial dysfunction but did not alter
mechanical properties. However, it is to mention that
this study was performed in a different vascular bed and
size (femoral artery).
We performed histological analyses on cross sections
of the mesenteric resistance arteries to gain insight into
potential mechanisms responsible for the observed func-
tional difference. The content of collagen IV was nor-
malized in both ZDF+S+E and ZDF+S+H vessels to the
levels of the ZDF animals with normal salt intake. Addi-
tionally, there was no effect of treatment in the ZDF+S
rats with respect to the elastin content within the vessel
wall.
At this time we can only speculate on possible other
mechanisms, like fibronectin-content [9] or the arrange-
ment of elastin [26]. Eplerenone reduced carotid artery
stiffness in aldosterone-infused salt-loaded rats [9,11] in
association with differences in fibronectin, but not in
collagen or elastin density. Studies on human [27] and
rat [28] cardiac myofibroblasts support a direct and
blood pressure-independent effect of aldosterone on car-
diac fibrosis. Previous studies demonstrated a beneficial
effect of spironolactone on vascular hypertrophic remo-
delling and vascular function of mesenteric arteries in
aldosterone-infused rats [13,14].
Some studies also show the effect of different levels
of salt intake on aldosterone-induced end organ
damage in hypertension. Most studies investigating the
effect of aldosterone are performed in a salt-loaded
state [3-5,7,9,18,19]. In a previous study in SHRSP rats
we found an effect of eplerenone on resistance arteries
only in salt-loaded animals [29]. High-salt induced car-
diac hypertrophy and fibrosis in normotensive Wistar
rats [30] and media hypertrophy in salt-fed normoten-
sive Sprague-Dawley rats [31] could be prevented by
spironolactone. Interestingly, both cardiac ventricles
are affected by diabetes. A recent study showed
decreased left and right ventricular function in ZDF
rats [32]. However, the remodelling of the ventricles
was found to be different with hypertrophy of the car-
diomyocytes in the left ventricle and dilatation of the
right ventricle without hypertrophy. An enhancement
of local cardiac aldosterone production has been
reported both in SHRSP compared with WKY rats [22]
and under salt treatment in SHRSP [21] and WKY rats
[33]. Therefore aldosterone associated end-organ
damage may be attributed to direct effects of aldoster-
one on cardiovascular tissues. Moreover, we reported
salt-sensitive blood-pressure in this ZDF model, which
may be attributable to inadequate high levels of aldos-
terone and altered expression of renal SGK-1 depen-
dent sodium transporter under high-salt treatment
[24]. Under normal-salt conditions aldosterone levels
are higher with less end-organ damage and less effect
of aldosterone antagonism. This supports the degree to
which high salt sensitizes tissues to aldosterone-
induced cardiovascular injury.
A recent publication showed relevant gender differ-
ences in ZDF rats in development of diabetes, which is
likely due to gender differences of hepatic anabolic path-
ways [34]. Another recent study has stressed the impor-
tance of impaired suppression of hepatic glucose
production in ZDF rats [35]. Thus, we have to acknowl-
edge that our findings may only be attributable to male
ZDF rats.
Conclusion
Findings from the present study indicate a pivotal role
of the level of salt intake on the effect of aldosterone on
vascular changes in diabetes mellitus. Our data provide
important insights into the pathophysiological signifi-
cance of salt in the role of mineralocorticoids such as
aldosterone, and the therapeutic potential for mineralo-
corticoid receptor blockade for protection of the vascu-
lature in diabetes mellitus. In summary our data suggest
that consequent mineralocorticoid receptor antagonism
might be an adjuvant therapy in preventing vascular
complications of diabetes mellitus.
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